Markets India

Sun Pharma's Q2FY27 net profit fell 36% year-on-year to Rs 1,989 crore due to litigation and acquisition costs, according to ET Markets.

Sun Pharma Q2 Net Profit Drops 36% on Litigation Costs

Sun Pharma reported a 36% year-on-year decline in Q2FY27 net profit to Rs 1,989 crore, driven by exceptional litigation and acquisition-related expenses. Revenue grew 11.8% to Rs 16,100 crore, fueled by strong domestic and emerging market sales, while US formulation sales dropped 8.2% to $455 million. India formulations sales rose 17.3% to Rs 5,552 crore, representing 34.5% of total revenue. Emerging market formulation sales grew 7.6% to $350 million. EBITDA increased 4.8% to Rs 4,744 crore, but operating margins contracted to 29.3% from 31.3%. R&D spending hit Rs 778 crore, or 4.8% of quarterly sales. Adjusted net profit for the quarter was Rs 3,162 crore.

The profit decline underscores the financial strain of litigation and acquisitions, which could pressure short-term profitability. However, growth in India and emerging markets signals resilience in core markets, while US sales weakness highlights reliance on mature markets. The company’s R&D investment and pipeline expansion position it for long-term innovation, though regulatory and litigation risks remain.

Direct stakeholders, including investors and shareholders, face pressure from the profit decline and rising costs. Competitors in the pharmaceutical sector may see shifting market dynamics due to Sun Pharma’s strategic moves. Emerging market partners benefit from expanded sales growth. Risks include persistent litigation costs, US market underperformance, and regulatory delays for the Organon acquisition. Opportunities lie in India and emerging market expansion, plus product portfolio enhancements from Ilumya approvals and lerodalcibep licensing.

The outcome of ongoing litigation and integration progress will shape Sun Pharma’s future profitability and strategic direction. The company’s first-half FY27 results, showing 11% revenue growth and 2.2% adjusted net profit rise, reflect a mixed performance amid challenges.

Integration planning for the Organon acquisition continues as scheduled. Regulatory approvals in remaining jurisdictions are progressing. Pre-launch activities for lerodalcibep in the EU are underway. Sun Pharma will report first-half FY27 results, with revenue and adjusted net profit growth.

Sun Pharma’s Q2 profit decline highlights litigation and acquisition costs, but revenue growth in key markets signals resilience.

Topics: Pharmaceuticals, Financial Results, Litigation, Revenue Growth, India Market, Emerging Markets, R&D Investment, Organon Acquisition

#SunPharma #Q2FY27Results #LitigationCosts #Pharmaceuticals #IndiaMarket #EmergingMarkets #RNDInvestment #OrganonAcquisition

Source: ET Markets